乳房整形技术在乳腺癌手术中的应用

注册号:

Registration number:

ChiCTR1900026340 

最近更新日期:

Date of Last Refreshed on:

2019-09-30 23:34:01 

注册时间:

Date of Registration:

2019-09-30 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

乳房整形技术在乳腺癌手术中的应用

Public title:

Application of mastoplasty in breast cancer surgery

注册题目简写:

English Acronym:

研究课题的正式科学名称:

乳房整形技术在乳腺癌手术中的应用

Scientific title:

Application of mastoplasty in breast cancer surgery

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

姜润学 

研究负责人:

蔡海峰 

Applicant:

Runxue Jiang 

Study leader:

Haifeng Cai 

申请注册联系人电话:

Applicant telephone:

+86 15076231393

研究负责人电话:

Study leader's
telephone:

+86 13303050005

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

15076231393@163.com

研究负责人电子邮件:

Study leader's E-mail:

13303050005@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

河北省唐山市路南区胜利路65号

研究负责人通讯地址:

河北省唐山市路南区胜利路65号

Applicant address:

65 Shengli Road, Lunan District, Tangshan, Hebei, China

Study leader's address:

65 Shengli Road, Lunan District, Tangshan, Hebei, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

唐山市人民医院

Applicant's institution:

Tangshan People's Hospital

研究负责人所在单位:

唐山市人民医院

Affiliation of the Leader:

Tangshan People's Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

RMYY-LL-2011-012

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

唐山市人民医院伦理委员会

Name of the ethic committee:

Ethics Committee of Tangshan People's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2011-01-17 00:00:00

伦理委员会联系人:

胡万宁

Contact Name of the ethic committee:

Wanning Hu

伦理委员会联系地址:

河北省唐山市路南区胜利路65号

Contact Address of the ethic committee:

65 Shengli Road, Lunan District, Tangshan, Hebei, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

唐山市人民医院

Primary sponsor:

Tangshan People's Hospital

研究实施负责(组长)单位地址:

河北省唐山市路南区胜利路65号

Primary sponsor's address:

65 Shengli Road, Lunan District, Tangshan, Hebei, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

河北省

市(区县):

唐山

Country:

China

Province:

Hebei

City:

Tangshan

单位(医院):

唐山市人民医院

具体地址:

路南区胜利路65号

Institution
hospital:

Tangshan People's Hospital

Address:

65 Shengli Road, Lunan District

经费或物资来源:

河北省卫生厅资助2万元;唐山市人民医院资助2万元;自筹资金4万元

Source(s) of funding:

Hebei health department funded 20,000 yuan; Tangshan people's hospital funded 20,000 yuan; It raised 40,000 yuan.

研究疾病:

乳腺癌  

Target disease:

Breast Cancer

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

在过去的几十年里,接受[乳房重建的病人比例有明显的上升趋势。乳腺癌切除术后乳房重建提高了患者的生活质量和社会心理功能。从患者选择和成本效益的角度对手术进行科学评估是非常重要的。本课题研究胸筋膜双平面技术在乳腺癌手术中的应用。  

Objectives of Study:

Within the past few decades, there have been marked trends toward higher proportions of patients undergoing breast reconstruction. It increases patients' quality of life and psychosocial functioning that breast reconstruction after resection of breast cancers. It is very important that the surgery is scientifically evaluated in terms of patient selection and cost-effectiveness.In this study, the application of double plane technique of thoracic fascia in breast cancer surgery was studied.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

患有胶原血管性疾病,严重心脏、肝脏、肾脏、造血系统及精神、神经系统疾病,妊娠或哺乳期妇女。

Exclusion criteria:

Suffering from collagen vascular disease, serious heart, liver, kidney, hematopoietic system and mental and neurological diseases, pregnant or lactating women.

研究实施时间:

Study execute time:

From 2019-10-01 00:00:00 To 2020-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2019-10-01 00:00:00 To 2020-02-28 00:00:00

干预措施:

Interventions:

组别:

胸肌筋膜双平面组

样本量:

80

Group:

Pectoral fascia biplane group

Sample size:

干预措施:

胸肌筋膜双平面技术乳房重建术

干预措施代码:

Intervention:

Pectoral fascia biplane technique breast reconstruction

Intervention code:

组别:

自体肌皮瓣+假体组

样本量:

80

Group:

Autologous myocutaneous flap and prosthesis group

Sample size:

干预措施:

自体肌皮瓣+假体乳房重建术

干预措施代码:

Intervention:

Autologous myocutaneous flap and prosthetic breast reconstruction

Intervention code:

组别:

生物补片+假体组

样本量:

80

Group:

Biological patch and prosthesis group

Sample size:

干预措施:

生物补片+假体乳房重建术

干预措施代码:

Intervention:

Biological patch and prosthetic breast reconstruction

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河北省 

市(区县):

唐山 

Country:

China

Province:

Hebei

City:

Tangshan

单位(医院):

唐山市人民医院 

单位级别:

三级甲等 

Institution
hospital:

Tangshan People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

美容效果

指标类型:

主要指标

Outcome:

cosmetic outcome

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肢体功能恢复

指标类型:

主要指标

Outcome:

Limb function recovery

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

手术时间

指标类型:

主要指标

Outcome:

The operation time

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

带引流管时间

指标类型:

主要指标

Outcome:

Time with drainage tube

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

并发症

指标类型:

主要指标

Outcome:

complications

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

乳腺标本

组织:

Sample Name:

Breast specimens

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

女性

Gender:

Female

随机方法(请说明由何人用什么方法产生随机序列):

项目负责人应用随机数字表法

Randomization Procedure (please state who generates the random number sequence and by what method):

Random number table method was used by the project leader

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

open label

Blinding:

open label

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

有需求可以联系作者。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

You can contact the author if you need it.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

A standard data collection and management system include a CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2019-09-30 23:34:01